Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

910805

Sigma-Aldrich

mPEG12-hydrazide

average MN 650 (by NMR), chemical modification reagent carboxyl reactive, hydrazide, methoxy

Synonym(s):

Methoxy-PEG-HZ, Polyethylene glycol, mPEG-Hydrazide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C28H58N2O14
Molecular Weight:
646.77
UNSPSC Code:
51171641
NACRES:
NA.23

product name

mPEG12-hydrazide,

description

Ω-end: Hydrazide
α-end: methoxy

form

solid or liquid

mol wt

average Mn 650 (by NMR)

reaction suitability

reagent type: chemical modification reagent
reactivity: carboxyl reactive

color

colorless to white

Ω-end

hydrazide

α-end

methoxy

polymer architecture

shape: linear
functionality: monofunctional

storage temp.

−20°C

Related Categories

Application

Polyethylene glycols (PEGs) are FDA approved hydrophilic polymers. They are non-toxic, non-immunogenic and non-antigenic, and are widely used in a varity of biomedical applications such as bioconjugation, drug delivery, surface functionalization, and tissue engineering. Methoxy PEG Hydrazide reacts with aldehydes and ketones to give stable hydrazones in a single step; it can also react with activated carboxylic acids.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Progress on Nonviral Delivery for CRISPR/Cas9

CRISPR/Cas9 delivery via nonviral nanoparticles shows promising advancements for gene editing in disease treatment.

Progress on Nonviral Delivery for CRISPR/Cas9

CRISPR/Cas9 delivery via nonviral nanoparticles shows promising advancements for gene editing in disease treatment.

Progress on Nonviral Delivery for CRISPR/Cas9

CRISPR/Cas9 delivery via nonviral nanoparticles shows promising advancements for gene editing in disease treatment.

Progress on Nonviral Delivery for CRISPR/Cas9

CRISPR/Cas9 delivery via nonviral nanoparticles shows promising advancements for gene editing in disease treatment.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service